

## EDITORIAL



**Teresa Carvalho** <sup>1</sup>  
Member of the Editorial  
Board JSCMed

<sup>1</sup> Assistant Professor and  
Researcher, Faculty of Medicine,  
University of Lisbon, Portugal  
✉ [t.carvalho@medicina.ulisboa.pt](mailto:t.carvalho@medicina.ulisboa.pt)

“

*The future of  
molecular medicine  
will depend on  
coupling technical  
innovation  
with equitable  
implementation”*

## Molecular Medicine: Bridging Discovery and Clinical Transformation

**M**olecular medicine has rapidly evolved from a conceptual framework to a transformative discipline at the intersection of molecular biology and clinical practice. Rooted in the discovery of DNA's structure in 1953 and empowered by methodological breakthroughs such as recombinant DNA technology, the polymerase chain reaction, and more recently next-generation sequencing and CRISPR/Cas9 technology, this field has redefined how we understand, diagnose, treat, and prevent diseases.

In its early phases, molecular medicine focused on characterizing the molecular basis of disease, revealing how mutations in genes such as *TP53* and *BRCA1/2* disrupt cellular regulation and drive oncogenesis. Similar progress in neurology identified mutations in the *APOE* and *APP* genes as pivotal in Alzheimer's disease, and the *HTT* gene in Huntington's disease. These insights established the paradigm that many diseases originate in molecular derangements that can be precisely mapped in our genome.

Today, the field is defined by unprecedented technological sophistication. Next-generation sequencing enables comprehensive genomic and transcriptomic profiling, while single-cell and spatial transcriptomics deepen our understanding of cellular heterogeneity in both health and pathology. CRISPR-Cas9 genome editing now provides a platform for correcting pathogenic mutations and advancing gene-based therapies.

The clinical translation of these discoveries has been equally transformative. Personalized medicine, informed by genomic profiling, is now a cornerstone of oncology and increasingly of cardiovascular and neurological care. Targeted therapies such as imatinib for *BCR-ABL*-positive chronic myeloid leukaemia and trastuzumab for *HER2*-positive breast cancer exemplify the power of molecularly guided intervention. Furthermore, the advent of liquid biopsy technologies allows real-time monitoring of circulating tumour DNA, offering new avenues for early detection and therapeutic adaptation.

Yet challenges remain. Integrating multi-omics data into clinically actionable insights requires robust computational tools, and the ethical dimensions of genome editing and data privacy demand ongoing scrutiny. The future of molecular medicine will depend on coupling technical innovation with equitable implementation. Artificial intelligence and machine learning promise to synthesize molecular data into useful information for healthcare and to construct predictive models of disease, but they must be used responsibly.

Molecular medicine is no longer an emerging field—it is a defining force in modern healthcare, as demonstrated during the recent SARS-CoV-2 pandemic, where an impressive collaborative effort of scientists and physicians working together to understand the epidemiology and pathology of COVID-19 led to the development of a new class of vaccines at unprecedented speed, allowing control of the crisis.

Its trajectory demonstrates how discovery science can reshape clinical practice, transforming medicine from reactive care to proactive, precise, and preventative intervention. As we look forward, the imperative is clear: to ensure that the transformative potential of molecular medicine is translated into accessible benefits for all patients, not just a privileged few.

Teresa Carvalho  
Member of the Editorial Board (JSCMed)

“

*Molecular medicine is no longer an emerging field—it is a defining force in modern healthcare...*”

ADVERTISEMENT

## II Fórum de Medicina e Engenharia Biomédica

### Medicina Personalizada e Medicina Aeroespacial



Tens um projeto que seja focado em medicina personalizada ou medicina aeroespacial que envolva Medicina e Engenharia?



Envia o resumo do projeto para [scmed@scmed.pt](mailto:scmed@scmed.pt)


Data limite: 2 de novembro

Máximo 2500 caracteres

Estrutura: Título, Autor(es)/Orador, Afiliação, Palavras-Chave, Introdução, Metodologia, Resultados, Conclusão

# 25

## Novembro

 Faculdade de Medicina da Universidade de Lisboa

Inscrição gratuita obrigatória  
Por email para [scmed@scmed.pt](mailto:scmed@scmed.pt)